ArticleJournal of biomedicine & biotechnology2009
Clinical significance of epigenetic inactivation of hMLH1 and BRCA1 in Tunisian patients with invasive breast carcinoma.
Article in Journal of biomedicine & biotechnology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Pooled it
- A Review of Cancer Genetics and Genomics Studies in Africa.Frontiers in oncology · 2020Review
- CpG methylation of APC promoter 1A in sporadic and familial breast cancer patients.Cancer biomarkers : section A of Disease markers · 2017Article
- Promoter Methylation Status of Breast Cancer Susceptibility Gene 1 and 17 Beta Hydroxysteroid Dehydrogenase Type 1 Gene in Sporadic Breast Cancer Patients.International journal of breast cancer · 2016Article
- Promoter methylation ofMolecular and clinical oncology · 2015Article
- MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Article
- Loss of WIF-1 and Wnt5a expression is related to aggressiveness of sporadic breast cancer in Tunisian patients.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Article
- Frequent CpG methylation of ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) in sporadic and hereditary Tunisian breast cancer patients: clinical significance.Medical oncology (Northwood, London, England) · 2013Article
- Aberrant promoter CpG methylation and its translational applications in breast cancer.Chinese journal of cancer · 2013Review
- Epigenome remodelling in breast cancer: insights from an early in vitro model of carcinogenesis.Breast cancer research : BCR · 2012Review
- Hypoxia-induced epigenetic regulation and silencing of the BRCA1 promoter.Molecular and cellular biology · 2011Article
- Use of ultra high performance liquid chromatography-tandem mass spectrometry to demonstrate decreased serum statin levels after extracorporeal LDL-cholesterol elimination.Journal of biomedicine & biotechnology · 2011Article
- Extracorporeal immunoglobulin elimination for the treatment of severe myasthenia gravis.Journal of biomedicine & biotechnology · 2010Article
- Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms.Breast cancer research : BCR · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aberrant hypermethylation of gene promoter regions is one of the mechanisms for inactivation of tumour suppressor genes in many human cancers including breast carcinoma. In the current study, we aimed to assess by MSP, the methylation pattern of two cancer-related genes involved in DNA repair: hMLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) and BRCA1 (breast cancer 1, early onset) in 78 primary breast cancers from Tunisian patients. The methylation frequencies were 24.36% for hMLH1 and 46% for BRCA1. BRCA1 methylation correlated with age at diagnosis (P = .015) and 5-years disease free survival (P = .016) while hMLH1 methylation was more frequent in larger tumors (P = .002) and in presence of distant metastasis (P = .004). Furthermore, methylation of hMLH1 significantly correlated with high level of P53 expression (P = .006) and with overall survival (P = .015) suggesting that silencing of hMLH1 through aberrant promoter methylation could be used as a poor prognosis indicator in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.